Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HP-001 Plus Dexamethasone for Relapsed/Refractory Multiple Myeloma With Extramedullary Disease
NCT07811986Phase 2Not yet recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Sep 2026
- Primary completion
- Dec 2027
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of HP-001 in multiple myeloma (MM), sponsored by Institute of Hematology and Blood Diseases Hospital. Primary endpoint: Overall Response Rate at 96 weeks. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
HP-001
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT07811986.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07811986.